Related Experiment Video
Updated: Jun 23, 2026
Simple Establishment of a Vascularized Osteogenic Bone Marrow Niche Using Pre-Cast Poly(ethylene Glycol) (PEG) Hydrogels in an Imaging Microplate
Published on: May 19, 2023
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer
E Amir1, M Trinkaus, C E Simmons
1Division of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Background:
Recent data have shown a fall in vascular endothelial growth factor (VEGF) concentrations after bisphosphonate (BP) treatment in BP-naïve patients. It has therefore been proposed that BPs may have in vivo anti-VEGF effects.
Aims:
To explore whether VEGF concentrations change after administration of a more potent BP in patients receiving long-term BP treatment.
Methods:
31 patients with breast cancer who had progressive metastatic bone disease despite treatment with early-generation BPs were switched to zoledronic acid. Serum VEGF concentrations were measured at baseline, and weeks 1, 2, 3, 4, 8 and 12.
Results:
VEGF concentration per platelet count did not change significantly at any time during the 12 weeks after treatment with zoledronic acid.
Conclusions:
Switching to zoledronic acid did not suppress circulating serum VEGF concentrations in BP-pretreated patients. Novel approaches to assess the effect of BPs on the bone milieu may provide further insight into the possible antiangiogenic properties of BPs.
More Related Videos
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
